JP2007512842A - シュードモナスにおける組換え二十面体ウイルス様粒子の生産 - Google Patents

シュードモナスにおける組換え二十面体ウイルス様粒子の生産 Download PDF

Info

Publication number
JP2007512842A
JP2007512842A JP2006542692A JP2006542692A JP2007512842A JP 2007512842 A JP2007512842 A JP 2007512842A JP 2006542692 A JP2006542692 A JP 2006542692A JP 2006542692 A JP2006542692 A JP 2006542692A JP 2007512842 A JP2007512842 A JP 2007512842A
Authority
JP
Japan
Prior art keywords
peptide
virus
cell
capsid
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006542692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512842A5 (https=
Inventor
ラソコバ，ラダ
ダオ，フィリップ，フック
Original Assignee
ダウ グローバル テクノロジーズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダウ グローバル テクノロジーズ インコーポレイティド filed Critical ダウ グローバル テクノロジーズ インコーポレイティド
Publication of JP2007512842A publication Critical patent/JP2007512842A/ja
Publication of JP2007512842A5 publication Critical patent/JP2007512842A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006542692A 2003-12-01 2004-12-01 シュードモナスにおける組換え二十面体ウイルス様粒子の生産 Pending JP2007512842A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52598203P 2003-12-01 2003-12-01
PCT/US2004/040117 WO2005067478A2 (en) 2003-12-01 2004-12-01 Recombinant icosahedral virus like particle production in pseudomonads

Publications (2)

Publication Number Publication Date
JP2007512842A true JP2007512842A (ja) 2007-05-24
JP2007512842A5 JP2007512842A5 (https=) 2008-01-17

Family

ID=34794205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542692A Pending JP2007512842A (ja) 2003-12-01 2004-12-01 シュードモナスにおける組換え二十面体ウイルス様粒子の生産

Country Status (10)

Country Link
US (1) US20050214321A1 (https=)
EP (1) EP1758925A4 (https=)
JP (1) JP2007512842A (https=)
KR (1) KR20060114340A (https=)
CN (1) CN101151272A (https=)
AU (1) AU2004313458B2 (https=)
BR (1) BRPI0417159A (https=)
CA (1) CA2547511A1 (https=)
MX (1) MXPA06006221A (https=)
WO (1) WO2005067478A2 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101237A1 (ja) * 2009-03-06 2010-09-10 アンジェスＭｇ株式会社 ポリペプチド及びその抗菌または消毒用途
WO2015005500A1 (en) * 2013-07-12 2015-01-15 Vlp Therapeutics, Llc Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
US8969311B2 (en) 2009-05-25 2015-03-03 Anges Mg, Inc. Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide
US9376470B2 (en) 2008-11-28 2016-06-28 Funpep Inc. Polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10098943B2 (en) 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US11345726B2 (en) 2012-02-16 2022-05-31 VLP Theranentics. Inc. Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
US12134777B2 (en) 2020-04-30 2024-11-05 Vlp Therapeutics, Inc. Alphavirus replicon vector and immunotherapy by administering same
US12227770B2 (en) 2017-12-20 2025-02-18 Vlp Therapeutics, Inc. Alphavirus replicon particle
US12280102B2 (en) 2020-04-17 2025-04-22 Vlp Therapeutics, Inc. Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1758925A4 (en) * 2003-12-01 2009-04-08 Dow Global Technologies Inc PRODUCTION OF A RECOMBINANT ICOSAHEDRIC VIRUS LIKE PARTICLE
WO2005086667A2 (en) * 2004-02-27 2005-09-22 The Dow Chemical Company High efficiency peptide production in plant cells
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
WO2007053188A2 (en) * 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
WO2008027099A2 (en) * 2006-05-30 2008-03-06 Dow Global Technologies Inc. Rpa optimization
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
US7998487B2 (en) * 2007-02-16 2011-08-16 The Salk Institute For Biological Studies Antitoxin and vaccine platform based on nodavirus VLPs
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
CA2765357A1 (en) * 2009-06-15 2010-12-23 Plant Bioscience Limited Production of viral capsids
RU2525136C1 (ru) * 2012-12-14 2014-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения препаративных количеств антигенов флоэмно-ограниченных вирусов
RU2555534C2 (ru) * 2013-05-23 2015-07-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения препаративных количеств вирусных частиц флоэмно-органиченных вирусов
CN103409377B (zh) * 2013-08-28 2015-12-23 中国农业科学院兰州兽医研究所 犬细小病毒病毒样颗粒的制备及用途
CN103882047B (zh) * 2014-03-18 2016-06-29 杨霞 重组人酸性成纤维细胞生长因子蛋白的制备方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN113278622B (zh) * 2021-06-09 2023-09-19 集美大学 一种变形假单胞菌适配体及其筛选方法
WO2024006433A1 (en) * 2022-06-30 2024-01-04 Carnegie Mellon University Method for production of virus-like particles for gene delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089455A2 (en) * 2002-04-22 2003-10-30 Dow Global Technologies Inc. Low-cost production of peptides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595658A (en) * 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4680264A (en) * 1983-07-01 1987-07-14 Lubrizol Genetics, Inc. Class II mobilizable gram-negative plasmid
US5281532A (en) * 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4637980A (en) * 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
US4695455A (en) * 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) * 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US5232840A (en) * 1986-03-27 1993-08-03 Monsanto Company Enhanced protein production in bacteria by employing a novel ribosome binding site
US5128130A (en) * 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US6054566A (en) * 1988-02-26 2000-04-25 Biosource Technologies, Inc. Recombinant animal viral nucleic acids
US5316931A (en) * 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5055294A (en) * 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5169760A (en) * 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
US5527883A (en) * 1994-05-06 1996-06-18 Mycogen Corporation Delta-endotoxin expression in pseudomonas fluorescens
AU702802B2 (en) * 1994-10-18 1999-03-04 Scottish Crop Research Institute Method of producing a chimeric protein
US5869287A (en) * 1996-07-12 1999-02-09 Wisconsin Alumni Research Foundation Method of producing particles containing nucleic acid sequences in yeast
KR100312456B1 (ko) * 1999-03-13 2001-11-03 윤덕용 슈도모나스 플루오레슨스 유래의 외래단백질 분비촉진유전자
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU2002339224B2 (en) * 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003103605A2 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
EP1758925A4 (en) * 2003-12-01 2009-04-08 Dow Global Technologies Inc PRODUCTION OF A RECOMBINANT ICOSAHEDRIC VIRUS LIKE PARTICLE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089455A2 (en) * 2002-04-22 2003-10-30 Dow Global Technologies Inc. Low-cost production of peptides

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376470B2 (en) 2008-11-28 2016-06-28 Funpep Inc. Polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes
JPWO2010101237A1 (ja) * 2009-03-06 2012-09-10 アンジェスＭｇ株式会社 ポリペプチド及びその抗菌または消毒用途
US8470765B2 (en) 2009-03-06 2013-06-25 Anges Mg, Inc. Polypeptides and antibacterial or antiseptic use of same
JP2015038108A (ja) * 2009-03-06 2015-02-26 アンジェスＭｇ株式会社 ポリペプチド及びその抗菌または消毒用途
JP2016104726A (ja) * 2009-03-06 2016-06-09 株式会社ファンペップ ポリペプチド及びその抗菌または消毒用途
WO2010101237A1 (ja) * 2009-03-06 2010-09-10 アンジェスＭｇ株式会社 ポリペプチド及びその抗菌または消毒用途
US9695219B2 (en) 2009-05-25 2017-07-04 Funpep Inc. Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide
US8969311B2 (en) 2009-05-25 2015-03-03 Anges Mg, Inc. Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide
US11345726B2 (en) 2012-02-16 2022-05-31 VLP Theranentics. Inc. Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
JP2016526374A (ja) * 2013-07-12 2016-09-05 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ Ｐｄ−１抗原またはｐｄ−１リガンド抗原を含むウイルス様粒子
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10464986B2 (en) 2013-07-12 2019-11-05 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
WO2015005500A1 (en) * 2013-07-12 2015-01-15 Vlp Therapeutics, Llc Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10098943B2 (en) 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
US12227770B2 (en) 2017-12-20 2025-02-18 Vlp Therapeutics, Inc. Alphavirus replicon particle
US12280102B2 (en) 2020-04-17 2025-04-22 Vlp Therapeutics, Inc. Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
US12134777B2 (en) 2020-04-30 2024-11-05 Vlp Therapeutics, Inc. Alphavirus replicon vector and immunotherapy by administering same

Also Published As

Publication number Publication date
AU2004313458A1 (en) 2005-07-28
CN101151272A (zh) 2008-03-26
EP1758925A4 (en) 2009-04-08
EP1758925A2 (en) 2007-03-07
MXPA06006221A (es) 2008-02-13
CA2547511A1 (en) 2005-07-28
US20050214321A1 (en) 2005-09-29
WO2005067478A3 (en) 2007-11-22
AU2004313458B2 (en) 2010-07-22
BRPI0417159A (pt) 2007-03-06
WO2005067478A2 (en) 2005-07-28
KR20060114340A (ko) 2006-11-06

Similar Documents

Publication Publication Date Title
JP2007512842A (ja) シュードモナスにおける組換え二十面体ウイルス様粒子の生産
US20090093019A1 (en) Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
JP6495690B2 (ja) 発現上昇のための細菌リーダー配列
JP2009501001A (ja) 多価ウイルス様粒子の製造
EP3388521A1 (en) High efficiency peptide production in plant cells
JP5176114B2 (ja) 細菌宿主細胞におけるマンニトール誘導のプロモーター系
JP2022512617A (ja) ラクトバチルス・カゼイ由来の二種類のプロモーターを用いた二種の目的タンパク質の同時表面発現ベクター、およびこれを用いたタンパク質の微生物表面発現方法
KR101183720B1 (ko) 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
JPH10508479A (ja) 天然疎水性ペプチドアナログとしての組換えペプチドの産生
JP2006506965A (ja) エンベロープをもつウィルスに対する組み換え抗ウィルスペプチドとその調製方法
CA2673593A1 (en) Immunologically enhanced recombinant vaccines
CN116376948B (zh) 一种质粒载体及展示外源蛋白的ms2噬菌体类似颗粒的制备方法
EP4286510A1 (en) Oral coronavirus infection vaccine
KR20260034705A (ko) 박테리오파지 t7 기반 유전자 전달체
Brown Bacteriophage Qβ: a versatile platform for Nanoengineering
MXPA06008061A (en) Expression of mammalian proteins in pseudomonas fluorescens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110301